title: Inhibitory effects of DuP 753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat.
abstract: The effects of the non-peptide antagonist DuP 753 and its metabolite EXP3174 on responses to angiotensin II were investigated in the pulmonary vascular bed of the intact-chest cat. Under conditions of controlled blood flow and constant left atrial pressure, injections of angiotensin II into the perfused lobar artery caused dose-related increases in lobar arterial pressure. Responses to angiotensin II were reproducible and were not changed by meclofenamate or prazosin, indicating that prostaglandin or norepinephrine release does not mediate or modulate pulmonary vascular responses to the peptide. DuP 753 (1-5 mg/kg iv) decreased responses to angiotensin II in a competitive manner, and the duration of the blockade was related to dose of the antagonist. DuP 753 had no significant effect on responses to U-46619, norepinephrine, serotonin, endothelin-1, vasopressin, or BAY K 8644. EXP3174 also decreased responses to angiotensin II without altering responses to agents that act by a variety of mechanisms. The inhibitory effect of EXP3174 (1 mg/kg iv) was not overcome by angiotensin II in the range of doses studied, and the shift to the right of the dose-response curve was nonparallel, suggesting that the blockade was noncompetitive. The blockade was long in duration, and, when the dose of EXP3174 was decreased to 0.1 mg/kg iv, the blockade was surmounted and the shift to the right of the dose-response relationship was parallel. DuP 753 and EXP3174 had little effect on mean baseline pressures in the cat.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana 70112.
authors: T J
authors: TJ
authors: McMahon
authors: A D
authors: AD
authors: Kaye
authors: J S
authors: JS
authors: Hood
authors: R K
authors: RK
authors: Minkes
authors: B D
authors: BD
authors: Nossaman
authors: P J
authors: PJ
authors: Kadowitz
mesh_terms: D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D001784:Blood Gas Analysis; D002415:Cats; D016232:Endothelins / Q000494:pharmacology; D005260:Female; D006863:Hydrogen-Ion Concentration; D007093:Imidazoles / Q000494:pharmacology*; D019808:Losartan; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D011652:Pulmonary Circulation / Q000187:drug effects*; D012701:Serotonin / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology*; D014667:Vasopressins / Q000494:pharmacology
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D016232:Endothelins; D007093:Imidazoles; D013777:Tetrazoles; D014667:Vasopressins; D000804:Angiotensin II; D012701:Serotonin; C066026:losartan carboxylic acid; D019808:Losartan; D009638:Norepinephrine